Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine
Does SaNOtize Hold An Edge?
Executive Summary
With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?
You may also be interested in...
G20 Meets Fresh Wave Of COVID With ‘Be Prepared’ Motto, Digital Focus
As the COVID-19 graph trends upward in countries like India, preparing for future pandemics is high on the agenda of intergovernmental forum G20. Digital healthcare and governance tools, One Health approach and tackling AMR emerged as focus areas at the recent meeting of its Health Working Group
BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic
Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics
Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead
Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.